- JD Health’s revenue for the third quarter reached 13.30 billion yuan, marking a 15% increase compared to the previous year.
- Operating income improved significantly to 551.7 million yuan from 174.6 million yuan in the same period last year.
- The company’s non-IFRS operating profit saw a 16% growth, reaching 861.8 million yuan.
- Analyst recommendations include 19 buys, 3 holds, and 2 sells.
“`
A look at JD Health International Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
JD Health International, a company operating drug stores in China, is poised for strong long-term growth according to Smartkarma Smart Scores analysis. With top scores in Growth and Resilience, the company is in a solid position to capitalize on expanding opportunities in the healthcare sector. Its robust momentum and high value score further indicate a promising outlook for investors.
While JD Health International excels in growth potential and resilience, its lower score in Dividend may not appeal to income-oriented investors. Nonetheless, the company’s overall positive Smart Scores highlight its strong position in the market, particularly in promoting health and wellness products in China. Investors looking for growth opportunities may find JD Health International a compelling prospect based on the analysis provided.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
